1. Home
  2. KALA vs CPHI Comparison

KALA vs CPHI Comparison

Compare KALA & CPHI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • KALA
  • CPHI
  • Stock Information
  • Founded
  • KALA 2009
  • CPHI N/A
  • Country
  • KALA United States
  • CPHI China
  • Employees
  • KALA N/A
  • CPHI N/A
  • Industry
  • KALA Biotechnology: Pharmaceutical Preparations
  • CPHI Biotechnology: Pharmaceutical Preparations
  • Sector
  • KALA Health Care
  • CPHI Health Care
  • Exchange
  • KALA Nasdaq
  • CPHI Nasdaq
  • Market Cap
  • KALA 5.1M
  • CPHI 5.3M
  • IPO Year
  • KALA 2017
  • CPHI N/A
  • Fundamental
  • Price
  • KALA $0.89
  • CPHI $1.65
  • Analyst Decision
  • KALA Buy
  • CPHI
  • Analyst Count
  • KALA 3
  • CPHI 0
  • Target Price
  • KALA $31.50
  • CPHI N/A
  • AVG Volume (30 Days)
  • KALA 1.6M
  • CPHI 9.1K
  • Earning Date
  • KALA 11-19-2025
  • CPHI 11-12-2025
  • Dividend Yield
  • KALA N/A
  • CPHI N/A
  • EPS Growth
  • KALA N/A
  • CPHI N/A
  • EPS
  • KALA N/A
  • CPHI N/A
  • Revenue
  • KALA N/A
  • CPHI $4,052,266.00
  • Revenue This Year
  • KALA N/A
  • CPHI N/A
  • Revenue Next Year
  • KALA N/A
  • CPHI N/A
  • P/E Ratio
  • KALA N/A
  • CPHI N/A
  • Revenue Growth
  • KALA N/A
  • CPHI N/A
  • 52 Week Low
  • KALA $0.61
  • CPHI $1.20
  • 52 Week High
  • KALA $20.60
  • CPHI $3.35
  • Technical
  • Relative Strength Index (RSI)
  • KALA 39.51
  • CPHI 52.72
  • Support Level
  • KALA $0.61
  • CPHI $1.46
  • Resistance Level
  • KALA $0.70
  • CPHI $1.61
  • Average True Range (ATR)
  • KALA 0.09
  • CPHI 0.07
  • MACD
  • KALA 0.25
  • CPHI 0.02
  • Stochastic Oscillator
  • KALA 70.38
  • CPHI 92.86

About KALA KALA BIO Inc.

Kala Bio Inc is a biopharmaceutical company. The company is a clinical-stage biopharmaceutical company dedicated to researching, developing, and commercializing therapies for rare and severe eye diseases. KALA'smain product candidate, KPI-012, is a human MSC-S, which contains numerous human-derived biofactors, such as growth factors, protease inhibitors, matrix proteins, and neurotrophic factors that can potentially correct the impaired corneal healing that is an underlying etiology of multiple severe ocular diseases. Its MSC-S platform is for retinal degenerative diseases, such as Retinitis Pigmentosa and Stargardt Disease.

About CPHI China Pharma Holdings Inc.

China Pharma Holding Inc is a drug manufacturing company. It is mainly engaged in the development, manufacture, and marketing of pharmaceutical products for human use in connection with a variety of high-incidence and high-mortality diseases and medical conditions prevalent in the People's Republic of China. The company mainly manufactures pharmaceutical products in the form of dry powder injectables, liquid injectables, tablets, capsules, and cephalosporin oral solutions. The product line of the company includes cefaclor dispersible tablets, clarithromycin granules, roxithromycin dispersible tablets, andrographolide tablets, ozagrel sodium for injection, gastrodin injection and others.

Share on Social Networks: